Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148

1.

Effects of a home based exercise rehabilitation program for cancer survivors.

Stefani L, Klika R, Mascherini G, Mazzoni F, Lunghi A, Petri C, Petreni P, Di Costanzo F, Maffulli N, Galanti G.

J Sports Med Phys Fitness. 2018 Oct 1. doi: 10.23736/S0022-4707.18.08908-9. [Epub ahead of print]

PMID:
30293406
2.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID:
30014881
3.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

PMID:
29956884
4.

Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.

Mazzoni F, Petreni P, Perna M, Scotti V, Bongiolatti S, Livi L, Di Costanzo F, Voltolini L.

Tumori. 2018 Jun 1:300891618775204. doi: 10.1177/0300891618775204. [Epub ahead of print]

PMID:
29895214
5.

Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.

Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.

Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30.

PMID:
29846100
6.

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.

Bracarda S, Galli L, Maruzzo M, Lo Re G, Buti S, Favaretto A, Di Costanzo F, Sacco C, Merlano M, Mucciarini C, Zafarana E, Romito S, Maestri A, Giorgio CG, Ionta MT, Turci D, De Giorgi U, Procopio G, Cortesi E, Giannarelli D, Porta C.

Future Oncol. 2018 Jun;14(14):1347-1354. doi: 10.2217/fon-2017-0570. Epub 2018 May 18.

PMID:
29774766
7.

Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.

Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N.

Pancreas. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.

PMID:
29771769
8.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
9.

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.

Pastorino A, Di Bartolomeo M, Maiello E, Iaffaioli V, Ciuffreda L, Fasola G, Di Costanzo F, Frassineti GL, Marchetti P, Antoniotti C, Leone F, Zaniboni A, Aprile G, Zilocchi C, Sobrero A, Bordonaro R.

Clin Colorectal Cancer. 2018 Sep;17(3):e457-e470. doi: 10.1016/j.clcc.2018.03.002. Epub 2018 Mar 8.

10.

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.

Rosati G, Pinto C, Di Fabio F, Chiara S, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrara R, Antonuzzo L, Adua D, Racca P, Bilancia D, Benincasa E, Stroppolo ME, Di Costanzo F.

J Geriatr Oncol. 2018 May;9(3):243-248. doi: 10.1016/j.jgo.2018.01.009. Epub 2018 Feb 9.

11.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

12.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
13.

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S.

Cancer Med. 2017 Jul;6(7):1493-1499. doi: 10.1002/cam4.1028. Epub 2017 May 25.

14.

Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.

Antonuzzo L, Del Re M, Barucca V, Spada F, Meoni G, Restante G, Danesi R, Di Costanzo F, Fazio N.

Cancer Treat Rev. 2017 Jun;57:28-35. doi: 10.1016/j.ctrv.2017.05.001. Epub 2017 May 11. Review.

PMID:
28535439
15.

Trichilemmal cystis in metastatic melanoma: a case report.

Savarese I, Grazzini M, Gori A, D'Errico A, Doni L, Scarfì F, Covarelli P, Di Costanzo F, De Giorgi V.

Exp Oncol. 2017 Mar;39(1):86-87.

PMID:
28361863
16.

Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study.

Crocetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarella A; GRELL EUROCARE-5 Working Group.

Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S85-S91. doi: 10.1097/CEJ.0000000000000291.

PMID:
28005610
17.

Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement.

Gori S, Pinto C, Caminiti C, Aprile G, Marchetti P, Perrone F, Di Maio M, Omodeo Salè E, Mancuso A, De Cicco M, Di Costanzo F, Crispino S, Passalacqua R, Merlano M, Zagonel V, Fioretto L, Micallo G, Labianca R, Bordonaro R, Comandone A, Spinsanti S, Iacono C, Nicolis F; AIOM (Italian Medical Oncology Association) and AIOM Foundation.

Tumori. 2016 Dec 1;102(6):e25-e27. doi: 10.5301/tj.5000582.

PMID:
27791235
18.

hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.

Muratori L, Petroni G, Antonuzzo L, Boni L, Iorio J, Lastraioli E, Bartoli G, Messerini L, Di Costanzo F, Arcangeli A.

Onco Targets Ther. 2016 Oct 14;9:6325-6332. eCollection 2016.

19.

Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.

Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F.

Cancer Med. 2016 Nov;5(11):3272-3281. doi: 10.1002/cam4.888. Epub 2016 Oct 17.

20.

First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.

Camerini A, Chella A, Mazzoni F, Puccetti C, Donati S, Lunghi A, Petreni P, Tartarelli G, Serradori M, Di Costanzo F, Amoroso D.

J Chemother. 2017 Feb;29(1):38-41. doi: 10.1080/1120009X.2016.1219498. Epub 2016 Aug 16.

PMID:
27687319

Supplemental Content

Loading ...
Support Center